Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner. One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.
The Institute for Clinical and Economic Review is hosting a three-part colloquium series of 90-minute webinars with policy makers and experts from diverse perspectives to debate alternative pricing policy approaches for current and future treatments for COVID-19.
The first colloquium will cover cost-recovery pricing in which prices are set at a level needed to cover all the costs borne by the manufacturer in making the treatment.
Confirmed speakers include:
- Afton Cissell, JD, Senior Counsel to Congressman Lloyd Doggett (D-Tex)
- Ronny Gal, Analyst, Sanford C. Bernstein
- David Mitchell, Founder, Patients For Affordable Drugs
- Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Brigham and Women’s Hospital/Harvard Medical School.